Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2022 09:00 ET | Source: Senti Biosciences, Inc.

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is...
November 23, 2022 07:55 ET | Source: Senti Biosciences, Inc.

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and...
November 10, 2022 07:55 ET | Source: Senti Biosciences, Inc.

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
November 03, 2022 09:05 ET | Source: Senti Biosciences, Inc.

Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
October 28, 2022 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
October 05, 2022 08:01 ET | Source: Senti Biosciences, Inc.

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
September 20, 2022 16:02 ET | Source: Senti Biosciences, Inc.

Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
September 06, 2022 16:01 ET | Source: Senti Biosciences, Inc.

Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
August 19, 2022 16:05 ET | Source: Senti Biosciences, Inc.

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
August 15, 2022 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Reports Second Quarter Financial Results and Business Updates

- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - ...